Drug intelligence / Profile preview

GSK-3277509A

Development stage: Discontinued
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK-3277509A is an investigational influenza vaccine candidate developed by GlaxoSmithKline (GSK) Biologicals. It was designed for the prevention of influenza infection, specifically as part of research into H7N1 and related avian-origin influenza strains. The vaccine was evaluated in clinical trials for its immunogenicity and safety in adults aged 18 to 60 years. Its mechanism of action is based on stimulating an immune response against targeted influenza virus antigen, typical of inactivated or subunit influenza vaccines. Development has been discontinued and it is not marketed[1][2][8].

Beyond the preview

Go deeper on GSK-3277509A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK-3277509A.

Explore the full profile